FDA Clarifies Its Approach to Postmarket Studies and Clinical Trials

In a draft revision of an April 2011 guidance, the FDA has laid out its current thinking on when the agency may require postmarket studies or clinical trials for approved prescription drugs.
Source: Drug Industry Daily